

CANONIC

FROM GENETICS TO PRODUCT USING AI

A subsidiary of evogene

September 2023

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Canonic Ltd. (the “Company”) and its parent, Evogene Ltd. (“Evogene”), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered “forward-looking statements” as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the “PSLRA”) and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as “believe”, “expect”, “anticipate”, “should”, “planned”, “estimated”, “intend” and “potential” or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene’s and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation.Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading “Risk Factors”.

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

VISION

Provide tailored medical cannabis products to optimize consumer wellbeing.

OUR SOLUTION

Utilizing computational power, AI and extensive biological knowledge, we predict interactions between active cannabis chemical compounds and therapeutic and mental effects on the human body, and produce products designed for specific consumers.

Market & Challenges

Market Overview

Cannabis Sales Growth
$82.3 Billion by 2027

Source: https://www.marketsandmarkets.com/Market-Reports/cannabis-market-201768301.html

Market Segmentation

Primary Reasons for Cannabis Use



Consumers seek to **improve their wellness** for a better quality of life due to **divers reasons**

Source: https://newfrontierdata.com/product/cannabis-consumers-in-america-2023-part-1-an-overview-of-consumers-today/

The Challenge – Connecting Between the Plant and Our Body

Plant

Thousands of plant metabolites (Chemical compounds)

Cannabinoids

Terpenes

Flavonoids

Other



Human Endocannabinoid System

Still many signaling pathways to delineate



Challenge Complexity - Connecting between compounds and targets

Various active compounds
With unknown effect

Various symptoms/targets
With unknown effectors



Canonic's Solution

Multiple Possible Combinations



CANONIC

Data driven computational biology approach for the development of tailored wellness products


TECHNOLOGY

Introducing – *'Indicator AI'*

Leveraging computational power with unique databases to
(1) connect cannabinoids with targets, and
(2) harness plant genomics diversity, for the development of precise medical cannabis products

Product Definition

Desired traits

- Clinical effect
- Premium appearance
- Profitable production





Data – Canonic's Proprietary Variety Collection

Various geographics origins



Different active compounds





Distinct plant structures

Sativa Indica Ruderalis

Diverse genetic backgrounds



Tech-Engines: When Data Meets Computational Biology

Computational Genomics

Combining deep scientific know-how with Big Data and AI technology to tailor plant genetics for improvement of plant traits and development of unique cannabis products

ChemPass AI

GeneRator AI



Example 1- Connecting Cannabinoids to Human Receptors (targets)

- Binding prediction of full spectrum physiological effect

Compounds

	HR1	HR2	HR3	HR4	HR5	HR6	HR7	HR8
Cuminaldehyde	-8.127	-7.408	-5.339	-5.816	-5.784	-7.588	-6.604	-6.192
Cuminol	-7.232	-7.424	-5.616	-5.901	-5.49	-6.392	-6.098	-5.782
Cyanidin 3-glucoside	-10.22	-10.251	-7.354	-7.308	-7.127	-12.19	-6.235	-6.181
Cyantraniliprole	20	20	-7.148	20	-5.626	-6.476	-5.412	-5.465
Cyclic pyranopterin monophosphate	-7.364	-6.588	-4.878	-6.085	-4.48	-7.045	-5.497	-5.265
Cycloartenol	20	20	-7.483	-5.854	-6.783	-7.763	-5.274	-7.265
Cyfluthrin	-10.09	-10.101	-7.321	-6.438	-7.456	-10.1	-7.062	-7.714
Cynaroside	-10.63	-8.397	-7.194	-6.958	-6.959	-8.758	-6.789	-6.8
Cypermethrin	-10.07	-10.008	-7.909	-6.336	-8.36	-10.1	-7	-6.066
Cyprodinil	-7.479	-7.672	-7.028	-5.177	-6.369	-6.899	-5.588	-5.161
Cysteinylglycine	-5.235	-5.801	-3.486	-6.081	-3.878	-3.669	-3.487	-4.582
Cytidine	-7.841	-7.531	-5.629	-6.924	-7.125	-6.811	-5.459	-6.178
Cytidine monophosphate	-7.17	-7.534	-5.623	-7.54	-7.408	-7.324	-4.775	-5.432
Cytidine triphosphate	-6.201	-6.115	-6.103	-6.656	20	-6.957	-7.196	-4.884
d -bornesitol	-6.667	-6.442	-6.086	-5.855	-6.027	-5.856	-4.945	-4.92
D-2-Hydroxyglutaric acid	-4.96	-5.286	-3.573	-4.839	-3.285	-4.316	-4.132	-3.259
Daminozide	-5.81	-5.158	-3.04	-4.085	-4.117	-4.217	-4.007	20
D-Arabinose 5-phosphate	-6.111	-5.651	-4.063	-4.764	-4.064	-5.015	-4.201	-3.78
D-arabitol	-4.696	-4.548	-3.185	-3.851	-3.487	-3.256	20	20
Dattelic acid	-9.62	-8.825	-6.911	-5.414	-7.712	-9.006	-6.967	-6.184
dCDP	-7.373	-7.944	-6.625	-7.297	-3.81	-6.948	-6.281	-5.881
dCMP	-6.647	-7.49	-6.819	-7.397	-6.84	-7.185	-6.347	-5.458
dCTP	-6.262	-6.453	-7.053	-7.797	-3.153	-7.717	-6.818	-6.082
Decanal	20	20	20	20	20	20	20	20
Decanoic acid	20	20	20	20	20	20	20	20
Decanone-2	-5.547	-5.533	20	20	-3.43	-3.978	-3.329	-3.236
Dehydroascorbic acid	-6.636	-6.776	-5.149	-5.812	-5.528	-5.616	-4.808	-4.297
Dehydrocannabifuran	20	20	-6.413	20	-6.627	-7.246	-5.18	-6.269
dehydrocannabispiran	-8.229	-8.551	-5.965	-6.02	-6.661	-7.469	-5.863	-5.951
Delphinidin 3-glucoside	-10.93	-7.082	-7.235	-7.271	-5.978	-12.57	-6.573	-6.595
Delta1(2)-Tetrahydrocannabinol methyl	-9.082	-9.223	-6.443	-5.687	-6.172	-8.15	-4.782	-5.941
Delta-7-cis-iso-tetrahydrocannabivarin	-7.703	-8.404	-7.323	-5.363	-6.457	-6.808	-4.498	-5.487
Delta-8-tetrahydrocannabinol	-7.91	-9.117	-7.442	-6.152	-6.847	-7.912	-5.748	-5.381
Delta-9-cis-tetrahydrocannabinol	-10.48	-9.622	-6.951	-5.477	-6.528	-6.874	-5.046	-6.742
Delta-9-tetrahydrocannabinol	-10.83	-10.029	-6.632	-6.048	-7.978	-7.862	-5.184	-7
Delta-9-tetrahydrocannabinol-C4	-10.8	-10.016	-6.596	-6	-6.773	-7.707	-5.012	-7.28
Delta-9-tetrahydrocannabinolic acid A	-10.15	-10.247	-6.864	-5.927	-5.729	-7.622	-5.326	-5.002
Delta-9-tetrahydrocannabinolic acid B	20	-9.376	-6.817	-5.841	-7.614	-8.204	-4.879	-5.694
Delta-9-tetrahydrocannabiorcol	-10.23	-9.379	-6.83	-6.099	-7.018	-7.714	-4.812	-6.839
Delta-9-tetrahydrocannabiorcolic acid	-9.408	-9.153	-6.092	-5.925	-5.872	-8.344	-5.935	-6.259
Delta-9-tetrahydrocannabivarinic acid	-10.17	-10.122	-4.715	-5.905	-6.052	-7.741	-4.792	-6.226
Delta-9-tethydrocannabivarin	-10.69	-9.892	-7.505	-6.317	-7.052	-7.531	-4.855	-7.141
delta-Cadinene	-8.457	-8.042	-5.186	-6.274	-6.224	-7.347	-4.317	-5.94
Delta-Guaiene	-7.875	-7.831	-6.324	-5.69	-7.021	-7.602	-3.417	-5.993
Deltamethrin	-9.424	-9.435	-5.961	-5.438	-7.741	-8.81	-5.746	-5.586
delta-Tocopherol	-9.375	-8.954	-5.515	-5.776	-8.128	-8.768	-4.222	-5.594
Demethylphylloquinone	-7.96	-7.936	-7.378	-4.961	-9.288	-9.688	-6.916	-6.052
Denbinobin (5-hydroxy-3,7-dimethoxy-1	-8.573	-8.713	-6.389	-5.839	-5.608	-7.387	-5.658	-6.146
Deoxyadenosine	-8.313	-7.722	-6.41	-6.17	-7.341	-7.106	-5.559	-5.722
Deoxyadenosine monophosphate	-8.203	-7.519	-6.25	-7.07	-5.345	-6.446	-6.196	-5.264
Deoxycytidine	-7.91	-6.983	-6.372	-6.39	-7.195	-7.126	-6.157	-5.79
Deoxyguanosine	-8.479	-8.851	-7.569	-6.141	-7.498	-6.934	-5.408	-6.405
Deoxythymidine diphosphate-L-rhamnc	-6.785	-5.783	-7.11	-6.224	-5.934	-8.19	-7.073	-5.451
Deoxyuridine	-8.03	-7.632	-6.036	-6.559	-7.015	-7.264	-6.123	-5.27
D-Erythro-imidazole-glycerol-phosphat	-6.928	-6.208	-4.767	-5.387	-4.566	-5.701	-4.955	-4.228
D-Erythrose 4-phosphate	-6.529	-5.435	-4.281	-5.526	-3.657	-4.46	-4.016	-4.241
Desmosterol	-8.06	20	-6.694	-4.087	-4.998	-7.489	-4.967	-5.497

Receptors

High binding potential

Medium binding potential

Low binding potential

CANONIC

Example 2- Genomic Power

20% Increase in THC Content in Two Years



Improved target trait by **>20%**

at a 3X faster rate than the traditional industry

with proprietary THC markers


PRODUCTS

Product Design for Specific Consumers Needs

Tom, 38 - Architect

Indication - Combat veteran with PTSD

Need – Quality Sleep, Reduce Stress, Energy

Product preference - Inflorescences

Day Use - T20/C4 Sativa
Night Use - T20/C4 Indica

Ron, 27- Student & Triathlete

Indication - Suffered a car accident that left him in severe pain at age 19

Need - Pain Management

Product preference - Inflorescences

THC Rich + High Terpenes

Michelle, 53 - Tech Executive

Indication - Suffers from Type 2 diabetes

Need – Appetite Suppressant, Relaxation

Product preference - Oil / Non Smokables

Day Use - THCV
Night Use - T20/C4 Indica

Sarah, 70 - Retired

Indication – Early signs of neurodegeneration

Need – Reduce anxiety caused by fear of falling

Product preference – Oil / Non Smokables

CBDV

* These cases are for example purposes and are not based on real-life cases

The ‘G-nnovation’ Series

1st generation products launched in Oct 2021

Product 1: G150

IMC* category T15C3

- **18 %** THC
- High consumer rank

Product 2: G200

IMC* category T20C4

- **19 %** THC
- High consumer rank

*IMC- Israel Medical Cannabis agency in the Ministry of Health

The ‘High-bred’ Series

2nd generation products launch in Oct 2022

SYNERGY
Sativa
THC 24%

COMBO
Indica
THC 24%

MOSAIC
Indica
THC 23%

MASH KUSH
Indica
THC 24.4%

BLEND KUSH
Indica
THC 23.8%

TWO STARS
Sativa
THC 24.2%

SYNERGY

Potential THC: 18.5% – 25.83%

CBD: <1%

Plant Type: Sativa -dominant

Genetic Similarity: Super Lemon Haze

Dominant Terpenes

- b-Myrcene 40%
- b-Caryophyllene 18%
- a-Humulene 18%
- trans-b-Farnesene 7%
- D/L-Limonene 5%
- Linalool 5%
- Others 7%

MOSAIC

Potential THC: 18.64% – 25.35%

CBD: <1%

Plant Type: Indica

Genetic Source: G200 x Malawi

Dominant Terpenes

- b-Myrcene 45%
- b-Caryophyllene 23%
- Limonene 13%
- Guaiol 5%
- Others 15%



MASH KUSH

Potential THC: 17.37% – 24.4%

CBD: <1%

Plant Type: Indica-dominant

Genetic Similarity: Headband

Dominant Terpenes:

- Terpinolene 26%
- b-Caryophyllene 13%
- b-Myrcene 11%
- a-Humulene 11%
- trans-Ocimene 10%
- Limonene 6%
- trans-b-Farnesene 5%
- Others 18%

DOWNLOAD

The ‘Precise’ Series (under development)

launch expected in 2025

PRODUCT 1

- **Indication:** Inflammation
- **Pre-clinical study:** Hadassah medical center
- **Status:** product development
- **Expected launch:** 2025

PRODUCT 2

- **Indication:** Pain
- **Pre-clinical study:** Migal research center
- **Status:** product development
- **Expected launch:** 2025

Hadassah Medical Center

MIGAL Galilee Research Institute LTD.

Product Pipeline

Product Generations	Effect Program	Lead Compound	Commercial Products
Generation I Inflorescences & Oils	Relaxation/Inflammation Ver 1	THC	**G150 G200**
	Relaxation/Inflammation Ver 2	THC	**G150, G200, G300, G400**
Generation II Inflorescences & Oils	Reduce Pain Ver1	THC RICH	**Synergy, Combo, Mosaic, Blend Kush, Two Stars, Mash Kush**
	Reduce Pain Ver2	THC RICH + HIGH TERPENES	**'Nature' series (mutual brand) Expected 2023**
	Inflammation Reduction	CBG	**Expected 2023***
	Appetite Suppressant	THCV	**Expected 2024**
	Anti convulsant	CBDV	**Expected 2024**
Generation III Non Smokables	Inflammation Reduction	CBG	**Expected 2025**
	Appetite Suppressant	THCV	**Expected 2025**



PD Product definition · BR Breeding · VA Variety trial/ Pre-clinical/ · CP Commercial Production · PRDV Product development · Pre-launch · launch

*Subjected to new category opening by the IMCA (Yakar)

CANONIC

BUSINESS MODEL

Cannabis Value Chain – Seed to Sale

Products Powered by Genomics

ACTIVITY

Varieties Development	Seeds & Seedling Production	Cannabis Cultivation	Manufacturing	Distribution	Sales & Marketing	Patients
R&D Facilities	Propagation Farms	Cultivators	Extraction & Formulation	Regional Distributors	B2B2C Marketing to Pharmacies	

Canonic in the Cannabis Value Chain

Direct Sales Model – Canonic Brands

ACTIVITY

CANONIC CANONIC

Service providers

CANONIC

Varieties Development



R&D Facilities

Seeds & Seedling Production

Propagation Farm

Cannabis Cultivation

Cultivators

TelCann

PLANTIS

Manufacturing

Extraction & Formulation

TIKUN OLAM MEDICAL CANNABIS CANNBIT PHARMACEUTICALS LTD

cannassure

Distribution

Regional Distributors

novolog LOGISTICS BY NOVOLOG GROUP

Sales & Marketing

Patients



Canonic in the Cannabis Value Chain

Royalties Sales Model – Canonic Varieties

ACTIVITY

CANONIC

Varieties Development



R&D Facilities

CANONIC

Seeds & Seedling Production

Propagation Farm

Licensed Company

Cannabis Cultivation

Cultivators

Manufacturing

Extraction & Formulation

Distribution

Regional Distributors

Sales & Marketing

B2B2C Marketing to Pharmacies

Patients

PLANTIS

GROVIDA

SUMMARY

Team

Ofer Haviv
CEO

Yaron Eldad
CFO

Yaron Berger
EVP Business Development

Liat Foigel Wejgman
VP Human

Elena Huly
VP Marketing & Sales

Dr. Michi Brog
VP Breeding & Production

Board of Directors

Ofer Haviv
Chairman of the board

Evogene President & CEO

Sassi Masliah
Board member

Evogene VP
Corporate Development

Raanan Cohen
Business strategy

Former CEO Koor Industries

Dr. Arnon Heyman
Board member

Former CEO of Canonic

Prof. Itamar Grotto
Clinical Strategy

Clinical and regulatory;
Former Associate Director General
at the Israeli Ministry of Health

Advisory Board

Prof. Yossi Tam
Cannabinoid clinical research

Director, Multidisciplinary
Center for Cannabinoid Research
of the Hebrew University

Prof. Mike Barnes

Honorary Professor of
Neurological Rehabilitation
Chair of the
Cannabis Industry Council, UK

Dr. Konrad F Cimander
Specialist in addictional medicine

Deputy Chairman of the Medical
Cannabis Society (DMCG), Germany

Prof. Eliad Davidson

Director of the pain relief unit
In Hadassah Medical Center

Dr. Shai Leviatov
Plant breeding

Commercial varieties breeding
for more than 30 years
in top leading multinational
seeds companies

Dr. Yariv Brotman
Plant metabolic pathways

Ben Gurion University
& Max Planck Institute
of Molecular Plant Physiology

Global Footprint



Market Presence
IL - 110 Pharmacies

Future Market

Cannabis cultivation

Future Cultivation

Research & development

Summary

- Canonic's **distinct market advantage** is in mapping, decoding and stabilizing cannabis genetics for improved wellbeing products, and its marketing capabilities in the Israeli market.
- Canonic holds exclusive rights to Evogene's (NASDAQ, TASE: EVGN) state-of-the-art **computational genomics technology**, for medical cannabis product development.
- **First two products, 'G-nnovation'**, were launched in Israel in Oct 2021.
- **Second-generation products ver. 1, 'High-bred'**, initiated launch in Israel in Oct 2022, focus on the market needs for:
  a) Rich THC and enriched with a high proportion of terpenes.
  b) CBG
  c) Rare minor cannabinoids.
- **Second-generation products ver. 2, 'Nature'**, currently under cultivation in collaboration with Plantis, expected to reach the market in Sep 2023.
- Canonic aims to enter the **EU market** during 2024-2025.

CANONIC

Cultivated by Science

THANK YOU